Business Performance - Lucid Diagnostics achieved a record quarterly revenue of $1.2 million in Q3 2024, a 20% increase compared to the previous quarter[6] - EsoGuard test volume reached 2,787 in Q3 2024[6] - Over 7,000 firefighters have undergone EsoGuard esophageal precancer testing[6] - Year-to-date revenue for 3Q24 reached $3.149 million, a $1.761 million increase compared to $1.388 million in 3Q23[34] Strategic Accomplishments - The ESOGUARD BE-1 clinical validation study was accepted for peer-reviewed publication[8] - A key patent underlying EsoGuard received a Notice of Allowance[8] - Lucid Diagnostics met with CMS Medicare Administrative Contractor (MAC) Palmetto GBA's Molecular Diagnostics Program (MolDX) to discuss EsoGuard clinical evidence package for upcoming submission for Medicare coverage[8] Financials - Cash reserves decreased from $24.920 million in 2Q24 to $14.489 million in 3Q24, a decrease of $10.431 million[32] - Net loss for 3Q24 was $(12.371) million, compared to $(14.208) million in 3Q23, an improvement of $1.837 million[34] - Non-GAAP adjusted loss per share improved from $(0.22) in 3Q23 to $(0.20) in 3Q24[34] - Shares outstanding increased from 49.3 million in 2Q24 to 51.6 million in 3Q24, an increase of 2.3 million shares[32]

Core Points - PAVmed Inc. will host a business update conference call and webcast on November 13, 2025, at 8:30 AM ET, where the CEO will discuss the company's operations and growth strategy, and the CFO will present the third quarter 2025 financial results [1][2]. Company Overview - PAVmed Inc. is a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors. Its subsidiary, Lucid Diagnostics, focuses on cancer prevention with products like the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device, which are designed for early detection of esophageal precancer [4]. - Another subsidiary, Veris Health Inc., is dedicated to personalized cancer care through remote patient monitoring using implantable biologic sensors and connected external devices. Veris is also developing an implantable physiological monitor to work alongside chemotherapy ports [4].

Core Insights - PAVmed Inc. and its subsidiary Veris Health have entered the commercial phase of their partnership with The Ohio State University Comprehensive Cancer Center to enhance personalized cancer care through the Veris Cancer Care Platform [1][2] Company Overview - PAVmed Inc. is a diversified commercial-stage medical technology company operating in medical devices, diagnostics, and digital health sectors [5] - Veris Health, a majority-owned subsidiary of PAVmed, focuses on digital health and has developed a digital cancer care platform aimed at improving personalized cancer care through remote patient monitoring [5] Partnership Details - The partnership with OSUCCC – James aims to expand the clinical deployment of the Veris platform, which includes launching a clinical registry for patients enrolled in the program [2] - The Veris Cancer Care Platform features remote physiological data collection, symptom reporting, telehealth capabilities, and electronic health record integration [2][3] Platform Features - Patients enrolled in the Veris platform receive a VerisBox™ containing connected health care devices that transmit physiological data to a cloud-based clinician portal [3] - A patient portal allows symptom reporting and health tracking via a smartphone app, which also enables family members to participate in the patient's care journey [3] Future Developments - Veris is developing an implantable physiological monitor to be used alongside a vascular access port, enhancing the platform's clinical and commercial value by providing remote data independent of patient compliance [3]

Core Insights - Lucid Diagnostics Inc. has appointed Danielle Scelfo as Senior Vice President of Market Access & Government Affairs to enhance market access infrastructure and accelerate commercial coverage expansion for its EsoGuard Esophageal DNA Test [1][2] - The company is at a critical juncture, aiming to expand patient access to the EsoGuard test, with Medicare coverage anticipated following a positive MolDX CAC meeting [2][3] Company Overview - Lucid Diagnostics is a commercial-stage cancer prevention medical diagnostics company and a subsidiary of PAVmed Inc., focusing on patients with gastroesophageal reflux disease (GERD) who are at risk of esophageal precancer and cancer [3] - The EsoGuard test is the first and only commercially available tool designed for early detection of esophageal precancer in at-risk patients [3] Leadership and Experience - Danielle Scelfo brings over 25 years of experience in market access, reimbursement, and government affairs, having held senior roles in various diagnostics companies [2][3] - Her previous positions include Vice President at ClearNote Health and leadership roles at CareDx, Hologic, Adaptive Biotechnologies, and Genomic Health [2]